Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long-term follow-up of patients with relapsed b-ALL after allo-HSCT treated with CD19 CAR-T cell from recipients and donors

View Full Paper
Ask AI
Bookmark
Share

Authors

CLCan LiuQLQing Li

Discussion

Loading...

Member takes

Overview

Clinical outcomes in relapsed B-ALL patients show improved progression-free survival with recipient-derived CAR-T cells, indicating effective therapy.

Key Points

  • Evaluate clinical outcomes of anti-CD19 CAR-T cell therapy in relapsed B-ALL patients post-allo-HSCT.
  • Enrolled 23 relapsed B-ALL patients post-allo-HSCT from January 2019 to March 2024.
  • Divided patients into recipient and donor groups based on PBMC availability for CAR-T cell therapy.
  • Measured clinical response, donor chimerism, adverse events, CAR-T cell and IL-6 levels, and aGVHD.
  • Recipient group showed better progression-free survival and overall survival rates than donor group after 12 months.
  • No difference in complete response rates between groups at 28 days post-infusion.
  • Median IL-6 peak was higher and occurred earlier in donor group compared to recipient group.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e29ahttps://doi.org/10.1182/blood-2025-7670
View Full Paper
Ask AI
Bookmark
Share